Novel therapies for heart failure: Where do they stand?

Circulation Journal

Volumn 80, Issue 9, 2016, Pages 1882-1891

  Greenberg, Barry ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene transfer; Heart failure; Novel therapies

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GUANYLATE CYCLASE; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMECAMTIV MECARBIL; SERELAXIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR; TRV027; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URODILATIN; VASCULOTROPIN; VERICIGUAT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; OLIGOPEPTIDE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; RELAXIN; SARCOSINE-ARGINYL-VALYL-TYROSYL-ISOLEUCYL-HISTIDYL-PROLYL-ALANINE; SERELAXIN PROTEIN, HUMAN;

CARDIAC RESYNCHRONIZATION THERAPY; DEATH; ENDOTHELIUM CELL; GENE TRANSFER; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE EJECTION TIME; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOPLASMIC RETICULUM; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HEART; KIDNEY; PATHOPHYSIOLOGY; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL NATRIURETIC FACTOR; CLINICAL TRIALS AS TOPIC; HEART; HEART FAILURE; HUMANS; KIDNEY; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RELAXIN; VASODILATION;

EID: 84983261829     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-16-0742     Document Type: Review

References (100)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013; 127: e6-e245, doi:10.1161/01.cir.0000442015.53336.12.
2. Roger VL. Cardiovascular diseases in populations: Secular trends and contemporary challenges: Geoffrey Rose lecture European Society of Cardiology meeting 2014. Eur Heart J 2015; 36: 2142-2146.
3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606-619.
4. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-1133.
5. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, et al. Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology/ American Heart Association heart failure staging criteria in the community. Circulation 2007; 115: 1563-1570.
6. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-1852.
8. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
9. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction or pneumonia. JAMA 2013; 309: 355-363.
10. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries 1998-2008. JAMA 2011; 306: 1669-1678.
11. Greenberg B. Acute decompensated heart failure: Treatments and challenges. Circ J 2012; 76: 532-543.
12. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: Review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010; 7: 75-82.
13. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, et al. Activation of orphan receptors by the hormone relaxin. Science 2002; 295: 671-674.
14. Leo CH, Jelinic M, Parkington HC, Tare M, Parry LJ. Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. J Am Heart Assoc 2014; 3: e000493, doi:10.1161/JAHA.113.000493.
15. Du XJ, Hewitson TD, Nguyen MN, Samuel CS. Therapeutic effects of serelaxin in acute heart failure. Circ J 2014; 78: 542-552.
16. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, et al. First clinical experience with intravenous recombinant human relaxin in compensated heart failure. Ann NY Acad Sci 2009; 1160: 387-392.
17. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): A multicentre randomised placebo-controlled parallel-group dose-finding phase IIb study. Lancet 2009; 373: 1429-1439.
18. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2 for treatment of acute heart failure (RELAX-AHF): A randomised placebo-controlled trial. Lancet 2013; 381: 29-39.
19. Sato N, Takahashi W, Hirayama A, Ajioka M, Takahashi N, Okishige K, et al. Multicenter, randomized, double-blinded, placebo-controlled phase II study of serelaxin in Japanese patients with acute heart failure. Circ J 2015; 79: 1237-1247.
20. Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: Results from the RELAX-AHF trial. Eur Heart J 2014; 35: 1041-1050.
21. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Effect of serelaxin on cardiac, renal, hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: Correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206.
22. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29: 707-769.
23. Forssmann WG, Richter R, Meyer M. The endocrine heart and natriuretic peptides: Histochemistry, cell biology, functional aspects of the renal urodilatin system. Histochem Cell Biol 1998; 110: 335-357.
24. Saba SR, Ramirez G, Vesely DL. Immunocytochemical localization of ProANF 1-30, ProANF 31-67, atrial natriuretic factor and urodilatin in the human kidney. Am J Nephrol 1993; 13: 85-93.
25. Nagase M, Katafuchi T, Hirose S, Fujita T. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertens 1997; 15: 1235-1243.
26. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemo-dynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998; 274: F63-F72.
27. Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the treatment of acute decompensated heart failure: From preclinical to clinical studies. Eur Heart J 2015; 36: 715-723.
28. Drummer C, Kentsch M, Otter W, Heer M, Herten M, Gerzer R. Increased renal natriuretic peptide (urodilatin) excretion in heart failure patients. Eur J Med Res 1997; 2: 347-354.
29. Kentsch M, Ludwig D, Drummer C, Gerzer R, Muller-Esch G. Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure. Eur J Clin Invest 1992; 22: 662-669.
30. Kentsch M, Ludwig D, Drummer C, Gerzer R, Muller-Esch G. Haemodynamic and renal effects of urodilatin in healthy volunteers. Eur J Clin Invest 1992; 22: 319-325.
31. Mitrovic V, Luss H, Nitsche K, Forssmann K, Maronde E, Fricke K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: A double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005; 150: 1239.e1-1239.e8
32. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27: 2823-2832.
33. Wu J, You J, Wang S, Zhang L, Gong H, Zou Y. Insights into the activation and inhibition of angiotensin II type 1 receptor in the mechanically loaded heart. Circ J 2014; 78: 1283-1289.
34. Patel PA, Tilley DG, Rockman HA. Beta-arrestin-mediated signaling in the heart. Circ J 2008; 72: 1725-1729.
35. Felker GM, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor: Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail 2015; 3: 193-201.
36. Violin JD, Dewire SM, Barnes WG, Lefkowitz RJ. G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics. J Biol Chem 2006; 281: 36411-36419.
37. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010; 335: 572-579.
38. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC Jr. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011; 4: 770-778.
39. Soergel DG, Subach RA, Cowan CL, Violin JD, Lark MW. First clinical experience with TRV027: Pharmacokinetics and pharma-codynamics in healthy volunteers. J Clin Pharmacol 2013; 53: 892-899.
40. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 2016 July 6, doi:10.1016/j.cardfail.2016.07.001.
41. f inhibitor, ivabradine, in Japanese patients with chronic heart failure: A randomized, double-blind, placebo-controlled phase II study. Circ J 2016; 80: 668-676.
42. Tardif JC, O’Meara E, Komajda M, Bohm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507-2515.
43. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure: The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
44. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1: 103-111.
45. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. JAMA 2007; 297: 1883-1891.
46. Malik FI, Morgan BP. Cardiac myosin activation. Part 1: From concept to clinic. J Mol Cell Cardiol 2011; 51: 454-461.
47. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett 2010; 1: 472-477.
48. Teerlink JR. A novel approach to improve cardiac performance: Cardiac myosin activators. Heart Fail Rev 2009; 14: 289-298.
49. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzua P, et al. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 2010; 3: 522-527.
50. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study. Lancet 2011; 378: 667-675.
51. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378: 676-683.
52. Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol 2008; 52: 13-16.
53. Teerlink JR, Felker GM, McMurray JJ, Ponikowski P, Metra M, Filippatos GS, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study. J Am Coll Cardiol 2016; 67: 1444-1455.
54. Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing: Implications in hypertension. J Mol Cell Cardiol 2015; 83: 112-121.
55. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009; 122: 216-238.
56. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 1991; 69: 1088-1096.
57. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: A multiorgan roadmap. Circulation 2016; 134: 73-90.
58. Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, et al. Riociguat: Mode of action and clinical development in pulmonary hypertension. Chest 2016 June 2, doi:10.1016/j.chest.2016.05.024.
59. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, heart failure. J Am Coll Cardiol 2012; 60: 1455-1469.
60. Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, et al. Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Fail Rev 2013; 18: 123-134.
61. Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-329.
62. Ghio S, Bonderman D, Felix SB, Ghofrani HA, Michelakis ED, Mitrovic V, et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): Rationale and design. Eur J Heart Fail 2012; 14: 946-953.
63. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128: 502-511.
64. Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Curr Opin Pharmacol 2015; 21: 95-104.
65. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 2014; 16: 1026-1038.
66. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al; SOCRATES-REDUCED Investigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED Randomized Trial. JAMA 2015; 314: 2251-2262.
67. Ishikawa K, Tilemann L, Ladage D, Aguero J, Leonardson L, Fish K, et al. Cardiac gene therapy in large animals: Bridge from bench to bedside. Gene Ther 2012; 19: 670-677.
68. Fish KM, Ishikawa K. Advances in gene therapy for heart failure. Discov Med 2015; 19: 285-291.
69. Ishikawa K, Tilemann L, Fish K, Hajjar RJ. Gene delivery methods in cardiac gene therapy. J Gene Med 2011; 13: 566-572.
70. Ishikawa K, Aguero J, Naim C, Fish K, Hajjar RJ. Percutaneous approaches for efficient cardiac gene delivery. J Cardiovasc Transl Res 2013; 6: 649-659.
71. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
72. Louis JV, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013; 24: 59-67.
73. Harbison CE, Weichert WS, Gurda BL, Chiorini JA, Agbandje-McKenna M, Parrish CR. Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5. J Gen Virol 2012; 93: 347-355.
74. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Pogoda JM, et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther 2016; 23: 313-319.
75. Raake PW, Tscheschner H, Reinkober J, Ritterhoff J, Katus HA, Koch WJ, et al. Gene therapy targets in heart failure: The path to translation. Clin Pharmacol Ther 2011; 90: 542-553.
76. Pleger ST, Brinks H, Ritterhoff J, Raake P, Koch WJ, Katus HA, et al. Heart failure gene therapy: The path to clinical practice. Circ Res 2013; 113: 792-809.
77. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987; 61: 70-76.
78. Zima AV, Bovo E, Mazurek SR, Rochira JA, Li W, Terentyev D. Ca handling during excitation-contraction coupling in heart failure. Pflugers Arch 2014; 466: 1129-1137.
79. Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res 1994; 75: 434-442.
80. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995; 92: 778-784.
81. Chaudhri BB, del Monte F, Harding SE, Hajjar RJ. Gene transfer in cardiac myocytes. Surg Clin North Am 2004; 84: 141-159.
82. Bouyon S, Roussel V, Fromes Y. SERCA2a gene therapy can improve symptomatic heart failure in delta-sarcoglycan-deficient animals. Hum Gene Ther 2014; 25: 694-704.
83. Xin W, Li X, Lu X, Niu K, Cai J. Improved cardiac function after sarcoplasmic reticulum Ca(2+)-ATPase gene transfer in a heart failure model induced by chronic myocardial ischaemia. Acta Cardiol 2011; 66: 57-64.
84. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008; 15: 1550-1557.
85. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119.
86. 2+-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
87. Greenberg B, Yaroshinsky A, Zsebo KM, Butler J, Felker GM, Voors AA, et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: The CUPID 2 trial (calcium upregulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail 2014; 2: 84-92.
88. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 2016; 387: 1178-1186.
89. Mingozzi F, Anguela XM, Pavani G, Chen Y, Davidson RJ, Hui DJ, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 2013; 5: 194ra92.
90. Mattila M, Koskenvuo J, Soderstrom M, Eerola K, Savontaus M. Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure. J Gene Med 2016; 18: 124-133.
91. Kho C, Lee A, Jeong D, Oh JG, Gorski PA, Fish K, et al. Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. Nat Commun 2015; 6: 1-11.
92. Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish KM, Kohlbrenner E, et al. Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: A large animal model. J Am Coll Cardiol 2016; 67: 2032-2046.
93. Gao MH, Bayat H, Roth DM, Yao ZJ, Drumm J, Burhan J, et al. Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function. Cardiovasc Res 2002; 56: 197-204.
94. Gao MH, Lai NC, Roth DM, Zhou J, Zhu J, Anzai T, et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 1999; 99: 1618-1622.
95. Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, Ander A, et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 2002; 105: 1989-1994.
96. Roth DM, Gao MH, Lai NC, Drumm J, Dalton N, Zhou JY, et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 1999; 99: 3099-3102.
97. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
98. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neo-vascularization. Circulation 2003; 107: 1322-1328.
99. Sundararaman S, Miller TJ, Pastore JM, Kiedrowski M, Aras R, Penn MS. Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure. Gene Ther 2011; 18: 867-873.
100. Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: The STOP-HF randomized Phase II trial. Eur Heart J 2015; 36: 2228-2238.